EcoDrugPlus

Endothelin Receptor Type A

Ensembl ID : ENSNSUG00000004885
Gene Symbol: EDNRA
3 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Endothelin Receptor Type B

Ensembl ID : ENSNSUG00000009217
Gene Symbol: EDNRB
3 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSNSUG00000012095
Gene Symbol: EZH2
3 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Epidermal Growth Factor Receptor

Ensembl ID : ENSNSUG00000010339
Gene Symbol: EGFR
3 Cross references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Epoxide Hydrolase 2

Ensembl ID : ENSNSUG00000004993
Gene Symbol: EPHX2
3 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSNSUG00000016989
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSNSUG00000008483
Gene Symbol: ERBB3
3 Cross references
281 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSNSUG00000004236
Gene Symbol: ERBB4
3 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Receptor 1

Ensembl ID : ENSNSUG00000011583
Gene Symbol: ESR1
3 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Receptor 2

Ensembl ID : ENSNSUG00000018912
Gene Symbol: ESR2
3 Cross references
273 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Related Receptor Gamma

Ensembl ID : ENSNSUG00000012772
Gene Symbol: ESRRG
3 Cross references
272 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Exportin 1

Ensembl ID : ENSNSUG00000015814
Gene Symbol: XPO1
3 Cross references
306 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).